Clinical Trials
9
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
1
11.1%
Completed
4
44.4%
Not yet recruiting
1
11.1%
Recruiting
3
33.3%
No approval data available
- Volta Medical's AI-guided cardiac ablation combined with pulmonary vein isolation demonstrated 88% freedom from atrial fibrillation at 12 months, compared to 70% with standard treatment alone. - The TAILORED-AF trial, published in Nature Medicine, marks the first large-scale demonstration of AI benefits in interventional cardiology, involving 370 patients across 26 centers in 5 countries. - The groundbreaking study offers new hope for persistent AF patients, who represent 70% of the global AF population, with significantly improved outcomes despite longer procedure times.
- A groundbreaking clinical trial demonstrates that AI-guided cardiac ablation combined with pulmonary vein isolation achieves 88% success rate in treating persistent atrial fibrillation, compared to 70% with standard treatment alone. - The TAILORED-AF trial, involving 370 patients across 26 centers in 5 countries, shows particular benefits for patients with longer AF duration, marking a significant advancement in personalized cardiac treatment. - The AI-guided approach, while requiring longer procedure times, maintained similar safety profiles to standard treatment and represents the first successful application of artificial intelligence in directing cardiac intervention.
- Arecor Therapeutics' AT278 demonstrated an accelerated PK/PD profile in overweight and obese individuals with Type 2 diabetes, showing promise for improved glucose control. - AstraZeneca's Tezspire showed a numerical reduction in COPD exacerbations, though not statistically significant, offering potential benefits for patients with varying eosinophil levels. - Johnson & Johnson's Tremfya demonstrated a 73% clinical remission rate in ulcerative colitis and superior efficacy compared to Stelara in Crohn's Disease. - Nimbus Therapeutics' NDI-101150, an HPK1 inhibitor, showed clinical benefit in advanced solid tumors, including complete and partial responses in renal cell carcinoma patients.
